
Oral Contraceptive Pills Market Report 2026
Global Outlook – By Type (Combination, Progestin Only, Other Types), By Category (Generic, Branded), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel And NGO, Other Distribution Channels) – Market Size, Trends, Strategies, and Forecast to 2035
Oral Contraceptive Pills Market Overview
• Oral Contraceptive Pills market size has reached to $30.43 billion in 2025 • Expected to grow to $61.05 billion in 2030 at a compound annual growth rate (CAGR) of 15% • Growth Driver: Impact Of Escalating Healthcare Expenditure On The Oral Contraceptive Pills Market • Market Trend: Advanced Progestin-Only Oral Contraceptives-global-market-report" target="_blank">Contraceptives Transforming Women's Reproductive Health • North America was the largest region in 2025 and Middle East is the fastest growing region.What Is Covered Under Oral Contraceptive Pills Market?
Oral contraceptive pills refer to a contraceptive tablet that contains hormones that prevent the release of eggs from the ovaries. Oral contraceptives typically contain progestin and estrogen. Also known as the birth control pill it comprises hormones that prevent the emergence of eggs from the ovaries. Most oral contraceptives involve estrogen and progestin. The oral contraceptive pills market by type into the combination, progestin-only, others, by category into generic, branded, by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others.
What Is The Oral Contraceptive Pills Market Size and Share 2026?
The oral contraceptive pills market size has grown rapidly in recent years. It will grow from $30.43 billion in 2025 to $34.96 billion in 2026 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increasing awareness of family planning, availability of generic pills, supportive government healthcare policies, growing prevalence of unintended pregnancies, expansion of hospital pharmacy networks.What Is The Oral Contraceptive Pills Market Growth Forecast?
The oral contraceptive pills market size is expected to see rapid growth in the next few years. It will grow to $61.05 billion in 2030 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to rise in digital healthcare platforms, technological advancements in drug delivery, increasing women’s health initiatives, expansion of online retail channels, growing demand for personalized contraceptive solutions. Major trends in the forecast period include rise in hormonal contraceptive awareness, increasing adoption of online pharmacies, growth in generic oral contraceptives, focus on low-dose and non-hormonal pills, expansion of women’s health programs.Global Oral Contraceptive Pills Market Segmentation
1) By Type: Combination, Progestin Only, Other Types 2) By Category: Generic, Branded 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel And NGO, Other Distribution Channels Subsegments: 1) By Combination Pills: Monophasic Combination Pills, Multiphasic Combination Pills, Extended-Cycle Combination Pills 2) By Progestin-Only Pills: Daily Progestin-Only Pills, Progestin-Only Emergency Contraceptive Pills 3) By Other Types: Low-Dose Oral Contraceptive Pills, High-Dose Oral Contraceptive Pills, Non-Hormonal Oral Contraceptives (In Development Or Alternative Formulations)What Is The Driver Of The Oral Contraceptive Pills Market?
The rising healthcare expenditure is expected to propel the growth of the oral contraceptive pill market going forward. Healthcare expenditure refers to the total amount of resources, including financial resources, spent on healthcare services and products within a specific period. Rising healthcare expenditure enhances overall healthcare accessibility, facilitating increased adoption of oral contraceptive pills through improved access to family planning services, consultations, and affordable prescriptions, thereby driving market expansion. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, rising healthcare expenditures are driving the growth of the oral contraceptive pills industry.Key Players In The Global Oral Contraceptive Pills Market
Major companies operating in the oral contraceptive pills market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Zydus Lifesciences Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals, Mankind Pharma Ltd., Mayne Pharma, HLL Lifecare Limited, Famy Care Ltd., Mylan N.V., GlaxoSmithKline plc, Piramal Enterprises Ltd., Syzygy Healthcare, V Care PharmaGlobal Oral Contraceptive Pills Market Trends and Insights
Major companies operating in the oral contraceptive pill market are developing innovative products, such as progestin-only oral contraceptives, to meet larger customer bases, increase sales, and increase revenue. Progestin-only oral contraceptives are a type of birth control pill that contains only a synthetic form of the hormone progestin. For instance, in July 2023, Perrigo Company PLC, an Ireland-based manufacturer of oral contraceptive pills, announced U.S. Food and Drug Administration (FDA) approval for Opill. Opill, the inaugural over-the-counter birth control pill in the United States, signifies a groundbreaking advancement in women's reproductive health. As a progestin-only pill, Opill not only offers effective pregnancy prevention but also establishes a new level of accessibility for women. Its availability without a prescription has the potential to revolutionize contraception access, marking a significant milestone in women's reproductive choices. The introduction of Opill reflects Perrigo's steadfast dedication to delivering transformative solutions that genuinely enhance lives and exemplifies a commitment to pioneering impactful innovations in healthcare.What Are Latest Mergers And Acquisitions In The Oral Contraceptive Pills Market?
In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired the manufacturing facility of Teva Pharmaceutical Industries Ltd. for an undisclosed amount. Marksans gains ownership of a 47,597-square-meter facility, enabling the company to effectively double its current production capacity in India from 8 billion units per year. The expanded facility will be utilized for the manufacturing of various pharmaceutical products, including tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceutical Industries Ltd. is an Israel-based manufacturer of oral contraceptive pills.Regional Insights
North America was the largest region in the oral contraceptive pills market in 2025. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Oral Contraceptive Pills Market?
The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Oral Contraceptive Pills Market Report 2026?
The oral contraceptive pills market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Oral Contraceptive Pills Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $34.96 billion |
| Revenue Forecast In 2035 | $61.05 billion |
| Growth Rate | CAGR of 14.9% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Category, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Zydus Lifesciences Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals, Mankind Pharma Ltd., Mayne Pharma, HLL Lifecare Limited, Famy Care Ltd., Mylan N.V., GlaxoSmithKline plc, Piramal Enterprises Ltd., Syzygy Healthcare, V Care Pharma |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
